Mary Norton

Publications

• Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing. Allyse MA, Sayres LC, Havard M, King JS, Greely HT, Hudgins L, Taylor J, Norton ME, Cho MK, Magnus D, Ormond KE. Prenat Diagn. 2013: 1-6
• Effects of changes in prenatal aneuploidy screening policies in an integrated health care system. Norton ME, Nakagawa S, Norem C, Gregorich SE, Kuppermann M. Obstet Gynecol. 2013; 121 (2 Pt 1): 265-71
• Noninvasive prenatal testing for fetal aneuploidy: clinical assessment and a plea for restraint. Norton ME, Rose NC, Benn P. Obstet Gynecol. 2013; 121 (4): 847-50
• Transdisciplinary translational science and the case of preterm birth. Stevenson DK, Shaw GM, Wise PH, Norton ME, Druzin ML, Valantine HA, McFarland DA. J Perinatol. 2013; 33 (4): 251-8
• Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing. Goodspeed TA, Allyse M, Sayres LC, Norton ME, Cho MK. Trends Biotechnol. 2013; 31 (1): 7-9
• Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Chetty S, Garabedian MJ, Norton ME. Prenat Diagn. 2013; 33 (6): 542-6
• A first look at chorioamnionitis management practice variation among US obstetricians. Greenberg MB, Anderson BL, Schulkin J, Norton ME, Aziz N. Infect Dis Obstet Gynecol. 2012: 2012 628362
• Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context. Allyse M, Sayres LC, King JS, Norton ME, Cho MK. Hum Reprod. 2012; 27 (11): 3123-31
• Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson MW, Oepkes D, Hollemon D, Sparks AB, Oliphant A, Song K. Am J Obstet Gynecol. 2012; 207 (2): 137.e1-8
• Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Sayres LC, Allyse M, Norton ME, Cho MK. Prenat Diagn. 2011; 31 (11): 1070-6
• Management of pregnancy in women with genetic disorders, Part 1: Disorders of the connective tissue, muscle, vascular, and skeletal systems. Chetty SP, Shaffer BL, Norton ME. Obstet Gynecol Surv. 2011; 66 (11): 699-709
• Management of pregnancy in women with genetic disorders: Part 2: Inborn errors of metabolism, cystic fibrosis, neurofibromatosis type 1, and Turner syndrome in pregnancy. Chetty SP, Shaffer BL, Norton ME. Obstet Gynecol Surv. 2011; 66 (12): 765-76
• Nuchal translucency measurement in fetuses with spinal muscular atrophy. Zadeh N, Hudgins L, Norton ME. Prenat Diagn. 2011; 31 (4): 327-30